GleamWall
中文EN

WST WEST PHARMACEUTICAL SERVICES INC

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 105770 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.6%
TTM net income YoY29.9%
TTM EPS YoY32.0%
Revenue 3-yr CAGR5.1%
Net income 3-yr CAGR4.5%

Margins

Gross margin37.6%
Operating margin23.0%
Net margin18.8%
FCF margin13.3%
EBITDA margin28.4%

Returns

ROE21.2%
ROA15.6%
ROIC (approx.)23.0%
Asset turnover0.83x

Leverage & solvency

Liabilities / assets26.9%
Debt / equity0.07x
Current ratio2.82x
Interest coverage96.32x

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio-0.4%
Payout ratio9.8%
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$874.50M$872.30M$844.90M$805.00M$804.60M$766.50M$698.00M$748.80M
Cost of revenue$527.10M$543.10M$548.50M$501.10M$510.30M$492.60M$466.10M$475.20M
Gross profit$347.40M$329.20M$296.40M$303.90M$294.30M$273.90M$231.90M$273.60M
R&D expense$18.30M$19.70M$15.80M$21.80M$17.10M$19.10M$16.30M$18.50M
SG&A expense$112.90M$117.60M$99.50M$107.00M$102.70M$95.90M$88.00M$85.30M
Operating income$267.40M$179.10M$177.10M$156.60M$167.60M$153.70M$107.00M$159.60M
Interest expense$3.80M$2.60M$1.90M-$200,000$200,000$100,000$400,000-$800,000
Pretax income$267.70M$180.10M$180.10M$161.50M$171.90M$157.00M$110.50M$164.90M
Income tax$58.00M$32.20M$44.70M$33.30M$34.00M$30.20M$24.10M$36.80M
Net income$214.00M$154.00M$138.80M$132.10M$140.00M$131.80M$89.80M$130.10M
EBITDA$313.30M$225.30M$222.30M$203.60M$210.60M$195.10M$147.00M$200.30M
EPS (basic)3.042.171.93—1.941.821.24—
EPS (diluted)3.022.151.92—1.921.821.23—
Dividends declared per share0.22—0.220.220.220.210.21—
Weighted avg. shares (diluted)70.80M71.30M72.40M—72.60M72.50M73.00M—
Balance sheet
Cash & equivalents$464.10M$435.80M$521.40M$791.30M$628.50M$509.70M$404.20M$484.60M
Receivables$748.20M$712.00M$685.60M$574.40M$625.00M$582.40M$543.60M$552.50M
Inventory$464.70M$447.40M$452.60M$443.90M$438.00M$421.10M$388.70M$377.00M
Current assets$1.82B$1.81B$1.83B$1.98B$1.82B$1.68B$1.46B$1.54B
PP&E, net$1.67B$1.69B$1.70B$1.73B$1.74B$1.72B$1.63B$1.58B
Goodwill$108.70M$108.70M$109.20M$109.90M$110.60M$110.90M$107.50M$106.00M
Intangibles$6.20M$6.40M$7.00M$7.70M$8.90M$9.70M$10.00M$10.80M
Total assets$4.06B$4.08B$4.11B$4.27B$4.11B$3.95B$3.62B$3.64B
Current liabilities$644.30M$640.50M$674.00M$654.90M$635.40M$604.60M$526.70M$550.40M
Short-term debt$0$0$0$0$0$0$0$0
Long-term debt$202.90M$202.90M$202.80M$202.80M$202.70M$202.60M$202.60M$202.60M
Total debt$202.90M$202.90M$202.80M$202.80M$202.70M$202.60M$202.60M$202.60M
Total liabilities$1.09B$1.09B$1.12B$1.09B$1.05B$1.02B$935.10M$961.10M
Shareholders' equity$2.97B$2.99B$2.99B$3.18B$3.05B$2.93B$2.68B$2.68B
Net debt-$261.20M-$232.90M-$318.60M-$588.50M-$425.80M-$307.10M-$201.60M-$282.00M
Shares outstanding69.80M70.40M70.90M72.00M71.90M71.90M71.80M72.30M
Cash flow statement
Operating cash flow$189.50M$124.00M$89.90M$251.10M$197.20M$177.10M$129.40M$190.10M
Capital expenditure$39.10M$43.20M$42.70M$76.10M$63.30M$75.20M$71.30M$104.90M
Free cash flow$150.40M$80.80M$47.20M$175.00M$133.90M$101.90M$58.10M$85.20M
Investing cash flow$78.90M-$43.20M-$42.70M-$76.10M-$63.30M-$75.20M-$71.30M-$104.80M
Financing cash flow-$241.80M-$164.80M-$308.70M-$11.70M-$11.50M-$14.90M-$147.00M-$68.90M
Depreciation & amortization$45.90M$46.20M$45.20M$47.00M$43.00M$41.40M$40.00M$40.70M
Stock-based compensation$4.30M$10.90M$6.60M$6.70M$8.40M$7.40M$1.30M$4.30M
Dividends paid$15.50M$15.70M$15.80M$15.80M$15.10M$15.10M$15.20M$15.30M
Share buybacks$231.00M$156.70M$297.60M$0$0$500,000$133.50M$54.40M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.